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Abstract
Background: We previously demonstrated that polyphosphazenes, particularly PCEP, enhance immune responses
in mice immunized subcutaneously and intranasally. The objective of the present study was to investigate the
efficacy of polyphosphazenes as adjuvants when delivered through different routes of vaccine administration.
Methods: BALB/c mice were immunized through intranasal, subcutaneous, oral and intrarectal delivery with
vaccine formulations containing either influenza X:31 antigen alone or formulated in PCEP. Serum and mucosal
washes were collected and assayed for antigen-specific antibody responses by ELISA, while splenocytes were
assayed for antigen-specific cytokine production by ELISPOT.
Results: Intranasal immunization with PCEP+X:31 induced significantly higher IgA titers in all mucosal secretions
(lung, nasal, and vaginal) compared to the other routes. Serum analysis showed that all mice given the PCEP+X:31
combination showed evidence of enhanced IgG2a titers in all administered routes, indicating that PCEP can be
effective as an adjuvant in enhancing systemic immune responses when delivered via different routes of
administration.
Conclusions: We conclude that PCEP is a potent and versatile mucosal adjuvant that can be administered in a
variety of routes and effectively enhances systemic and local immune responses. Furthermore, intranasal
immunization was found to be the best administration route for enhancing IgA titers, providing further evidence
for the potential of PCEP as a mucosal adjuvant.
Background
The high costs associated with the treatment of infec-
tious diseases in humans or animals are a large financial
burden. Thus, prevention of infections by means of vac-
cination remains the most cost-effective biomedical
strategy. Since over 90% of infectious diseases are
initiated by pathogens that traverse mucosal surfaces,
stimulation of the mucosal immunity is the best
approach to control such infections and this is best
achieved through mucosal vaccination [1].
Mucosal vaccines need to induce immunity by at least
one of three ways. They must prevent 1) the etiological
agent from attachment and colonization at the mucosal
epithelium, 2) replication and growth of the agent in the
mucosa, and/or 3) toxins from attachment to their
respective target cells [1]. As such, one of the primary
determinants that would indicate enhanced mucosal
immune response/protection is secretory IgA, the most
abundant immunoglobulin found in human secretions.
Secretory IgA is transported into mucosal secretions
and is resistant to proteases, prevents adhesion of bac-
teria/toxins to target cells, and can neutralize viruses
and toxins, among other characteristics [1]. Unfortu-
nately, many mucosal vaccine candidates fail to stimu-
late a strong IgA immune response; as a result, only a
very few approved human mucosal vaccines exist, such
as Dukurol (cholera, oral route), and FluMist® (influenza,
intranasal) [1].
Mucosal administration of antigen without adjuvant
often induces tolerance and fails to induce immunity.
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break tolerance and lead to enhanced immune
responses. Therefore, adjuvants are critical for the suc-
cess of mucosal vaccines based on subunit antigens.
Adjuvants that have shown to highly promote mucosal
IgA and systemic IgG in mice include the cholera toxin
(CT) and E. coli heat-labile enterotoxin (LT) [2,3]. How-
ever, their toxicities, even in genetically detoxified deri-
vatives, make them unsuitable for human use. Other
adjuvants, such as CpG oligodeoxynucleotides (ODN),
can solely induce systemic and mucosal responses in
mice; however, in larger animals, much higher doses of
CpG are often required, which are not economically
viable for use in livestock considering the cost of CpG
ODN production [4]. As a result, CpG needs to be com-
bined with other adjuvants to optimize its efficacy. Thus,
there is a great need for safe and effective mucosal adju-
vants. One class of adjuvants that has garnered attention
in recent studies are polyphosphazenes. They are syn-
thetic and biodegradable polymers that comprise a
nitrogen and phosphosphorus backbone with organic
side chains bound to phosphorus [5]. They can also be
modified to include ionic groups which can increase
solubility in water.
Polyphosphazenes such as poly[di(carboxylatophenoxy)
phosphazene] (PCPP), have shown enhanced and long
lasting immune responses with a variety of viral and
bacterial antigens [6-10], including with influenza [5],
tetanus toxoid, hepatitis B surface antigen (HBsAg),
herpes simplex virus type 2 glycoprotein D [11], bovine
respiratory syncytial virus [12] and non-microbial anti-
gens such as bovine and porcine serum albumin [13,14].
Our previous studies showed that one of the newer
polyphosphazene polyacids, poly[di(sodiumcarboxyla-
toethylphenoxy)phosphazene] (PCEP) has been shown
to be more potent than PCPP in terms of quantity and
quality of immune responses [13,15]. Also, PCEP was
found to have long lasting [13], antigen-sparing effects
[13], reduced the number of immunizations needed to
induce similar immune responses from multiple immu-
nizations with antigen alone and demonstrated mucosal
adjuvant activity following IN delivery [15]. Cumula-
tively, these results demonstrate the potency of PCEP
and raise the possibility of the development of a single-
shot vaccine, which is highly sought not only as a cost-
effective measure, but also to improve compliance with
immunization schedules, particularly in developing
countries.
Building upon this concept, an adjuvant that can be
used in vaccine administered by a variety of routes
would be highly desirable in the vaccine industry. How-
ever, with the exception of a few experimental adju-
vants, many are not compatible with different routes of
immunization. To further explore the versatility of
PCEP, we investigated the adjuvant activity of PCEP
with influenza X:31 antigen when administered by par-
enteral (subcutaneous), and mucosal (intranasal, oral,
and intrarectal) routes. We show that, while PCEP has
adjuvant activity in all routes tested, intranasal immuni-
zation was superior in elevating IgA mucosal immune
r e s p o n s e sa n dm a yb eo p t i m a lf o rp r o t e c t i o na g a i n s t
influenza viruses.
Methods
Polymer synthesis and characterization
The polyphosphazene PCEP adjuvant was synthesized by
Idaho National Laboratory (Idaho Falls, ID, USA) using
methods described previously [9,16,17]. PCEP was found
to have endotoxin levels below 0.034 ng/ml as assessed
b yt h eL i m u l u sA m e b o c y t eL y s a t ea s s a y( B i o w h i t t a k e r ,
Walkersville, MD, USA). The synthesized polyphospha-
zenes were in a solid salt state and dissolved in Dulbec-
co’s PBS (Sigma, St. Louis, MO, USA) at a concentration
of 5 mg/ml and used appropriately in vaccine
formulations.
Preparation of influenza virus X:31 antigen
Purified influenza X:31 virus (A/Aichi/68 H3:N2) was
purchased from Charles River Laboratories (North
F r a n k l i n ,C T ,U S A ) .B r i e f l y ,t h eX : 3 1a n t i g e nw a sp r e -
pared from the virus stock by first diluting the virus
with an equal volume of PBS, and then solubilised by
adding and mixing Tween-80 to a final concentration of
0.25% at room temperature for 30 min. Subsequently,
an equal volume of ether was added to the solution, and
following another 30 min incubation with mixing, the
solution was centrifuged to separate the non-soluble
phases. The water-soluble phase was then collected and
dried in a fume hood to evaporate residual ether for 1-2
days. The “split antigen” (X:31) was then quantified by
the Quant-IT Protein Assay Kit (Invitrogen, OR, USA).
Animals and immunization
All animal experiments were conducted according to the
Guidelines for the Care and Use of Laboratory Animals
as indicated by the Canadian Council on Animal Care
and was approved by the Animal Care Committee of
t h eU n i v e r s i t yo fS a s k a t c h e w a n .B A L B / cm i c ew e r e
obtained from Charles River Laboratories (North Frank-
lin, CT, USA). PCEP was used at 50 μg per animal, and
the experimental vaccine was formulated by mixing
5.0 μg of X:31 split antigen with an aqueous solution
of PCEP.
A total of 8 random groups of BALB/c mice (n = 9
mice per group) were sedated and given a primary and
a secondary immunization 4 weeks apart of either PCEP
+ X : 3 1o rX : 3 1a l o n e .F o u rg r o u p so fm i c ew e r eg i v e n
PCEP+X:31 through four different administration routes:
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(IR) delivery (Table 1). The other 4 groups of mice were
given X:31 only using the same above routes. Immuniza-
tions were given in 20 μl delivery (for intranasal vaccina-
tion, 10 μl per nostril), except for the oral route, which
was given as a 50 μl volume. The immunization sche-
dule is summarised in Table 1. Mice were bled prior to
immunization (week 0) and subsequently at 2, 4, 6, and
8 weeks after the primary immunization. Any signs of
adverse reactions to the immunizations were monitored.
Vaginal washes were collected before immunization and
at 4 and 8 weeks. After 8 weeks, nasal and lung washes
were also collected and the spleens were dissected from
all animals in order to assay the antigen-specific cyto-
kines (IFN-g and IL-4) in splenocytes.
Collection of mucosal washes
Lung, nasal, and vaginal washes were collected using a
solution of the protease inhibitor Pefabloc SC
Plus (Roche,
Indianapolis, IN, USA). Pefabloc powder was dissolved in
PBSA and PSC protector solution as outlined by the
manufacturer’si n s t r u c t i o n st oaf i n a lc o n c e n t r a t i o no f
0.4 mM Pefabloc solution. For each wash, 100, 300, and
500 μl of Pefabloc solution was introduced into the vagi-
nal, nasal, and lung cavities, respectively, and subse-
quently withdrawn for collection. All samples were
promptly centrifuged and the resulting supernatants were
collected and assayed for antigen-specific antibodies.
Detection of influenza virus X:31- specific antibodies by
ELISA
Procedures to assay for X:31-specific antibodies were
followed as outlined previously [15] with minor modifi-
cations. Biotinylated goat-anti mouse IgG1 and IgG2a
antibodies (Caltag Laboratories, CA, USA) were diluted
1/10000 to assay antibody titers in serum. IgG and IgA
antibodies (Caltag) were used to analyze mucosal secre-
tions. IgG antibodies was diluted 1/10000, while IgA
was diluted to 1/5000. The sera from naïve, unimmu-
nized mice were used as negative controls.
Isolation of splenocytes
At the end of the 8 week experimental period, all of the
animals were euthanized and spleens were removed
similarly to previous experiments [15] with some modi-
fications. Isolated spleens were placed in cold, complete
MEM medium (Gibco, Carlesbad, CA, USA) containing
10 mM HEPES (Gibco) and 1X pen/strep antibiotics
(Gibco). Cells were obtained by teasing spleen tissue
with a syringe plunger through a 40 μm nylon cell strai-
ner (BD Falcon, San Jose, CA, USA). Sterile NH4Cl was
then added to the cell suspension to lyse erythrocytes
for one minute and complete MEM medium was
promptly added to prevent lysis of splenocytes. The
splenocytes were washed once with complete MEM
medium and resuspended in complete AIM V medium
(10 mM HEPES, 1X non-essential amino acids (Gibco),
1 mM sodium pyruvate, 50 mM 2-mercaptoethanol) to
a final concentration of 1 × 10
6 cells/ml. Cells were
counted using a Multisizer™ 3 Coulter Counter (Beck-
man Coulter, Mississauga, ON, CA) according to the
manufacturer’s instructions. Cell concentrations were
determined using software provided by the
manufacturer.
Detection of X:31-specific cytokine producing cells by
ELISPOT
T h ep r o t o c o lu s e dt oa s s a yf o rX : 3 1 - s p e c i f i cI F N - g and
IL-4 producing cells similarly followed an approach pre-
viously described [15] with a few modifications. Rat
anti-mouse IFN-g and IL-4 (BD Biosciences, Missis-
sauga, ON, CA) coated nitrocellulose microtiter plates
(Whatman, Florham Park, NJ, USA) were instead
washed and blocked with complete AIM V medium in a
37°C incubator. Splenocytes were added to these plates
at 1 × 10
6 cells/well in complete AIM V medium in tri-
plicate. Influenza X:31 antigen (1 μg/well) was added to
appropriate wells containing the spleen cells and incu-
b a t e da t3 7 ° Cf o r1 8h .T h eE L I S P O Ta s s a ya n dt h e
counting of developed spots on the nitrocellulose plates
were completed as previously described [15].
Statistical analysis
All data on total IgG, IgG1, IgG2a, and IgA antibody
titers in BALB/c mice were analyzed using GraphPad
Prism version 5.01 for Windows, GraphPad Software,
San Diego, California, USA, http://www.graphpad.com.
The mean serum titers for ELISAs were examined for
significance using repeated measures ANOVA with
Tukey’s Comparison of Rank Sum. Data from ELISPOT
assays and ELISAs of mucosal secretions were examined
using the Kruskal-Wallis test. If the means were found
to be significant, median ranks between pairs of groups
were performed using two-tailed Mann-Whitney U
tests. Mean comparisons were conducted to compare
Table 1 Immunization schedule
Group Vaccine
formulation
Primary
immunization
Secondary immunization
(at 4 weeks after primary)
1 PCEP + X:31
EP
IN IN
2 PCEP + X:31 SC SC
3 PCEP + X:31 Oral Oral
4 PCEP + X:31 IR IR
5 X:31 IN IN
6 X:31 SC SC
7 X:31 Oral Oral
8 X:31 IR IR
IN, intranasal; SC, subcutaneous; IR, intrarectal
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declared at p < 0.05.
Results
Antibody responses in serum of mice immunized using
different routes of administration
The ability of a vaccine to enhance immune responses
systemically is an important feature as infections can
often spread. We previously determined that PCEP did
not have an effect on its own in enhancing adaptive
immune responses [15]. Hence, we did not include this
control in the current studies. As such, to study the
effect of PCEP as an adjuvant, PCEP+X:31 or X:31 alone
were independently administered at four routes (IN, SC,
oral, IR). Serum was collected and analyzed for antigen-
specific antibodies.
Following primary IN immunization with X:31 alone,
there was very little induction of serum IgG1 titers up
to 4 weeks post immunization (Fig. 1A, open squares).
After the secondary IN immunization, IgG1 antigen-spe-
cific titers increased approximately 100-fold by the end
of the 8 week experiment (Fig. 1A, open squares, p <
0.05). In contrast, IN immunization of PCEP+X:31 sig-
nificantly enhanced IgG1 titers by approximately 1000-
fold as early as 2 weeks after immunization (Fig. 1A,
solid squares, p < 0.05) and remained steady for another
2w e e k s .As e c o n d a r yi m m u n ization with PCEP+X:31
further enhanced titers at least 10-fold at 6 weeks post
primary immunization (Fig. 1A, solid squares). This
observation confirmed that PCEP is a potent adjuvant
for IN immunization either as a single or multiple
immunization regimens.
Subcutaneous immunization with X:31 alone increased
IgG1 titers by 100-fold as early as 2 weeks post immuni-
zation (Fig. 1B, open circles, p < 0.05) with little addi-
tional increase in titers at 4 weeks. The secondary
immunization further enhanced titers by 10-fold at
6 weeks (Fig. 1B, open circles). Similar to IN immuniza-
tion, SC immunization with PCEP+X:31 greatly
increased the IgG1 response; after only 2 weeks, anti-
gen-specific titers increased 10,000-fold (Fig. 1B, solid
circles, p < 0.05). This response remained relatively con-
sistent throughout the 8 week experiment, even after
the second SC immunization (Fig. 1B). Thus, PCEP is a
potent adjuvant for a primary SC immunization.
Generally, oral immunization (Fig. 1C) did not induce
IgG1 titers as high as those seen from IN (Fig. 1A) or
SC (Fig. 1B) immunization. Mice given X:31 alone orally
showed very little serum IgG1 production from the first
immunization and only after a secondary immunization,
at the end of the 8 week experiment, did IgG1 titers
increase approximately 10-fold (Fig. 1C, open triangles).
When given PCEP+X:31, X:31-specific IgG1 titers were
enhanced 10-fold at 2 weeks after primary immunization
with a further 10-fold increase 2 weeks later (Fig. 1C,
solid triangles). The secondary oral immunization with
PCEP+X:31 did not further enhance IgG1 titers until 8
weeks, where titers slightly increased (Fig. 1C, solid tri-
angles). Thus, PCEP has adjuvant activity when given by
oral route.
Interestingly, the effect of PCEP was negligible when
g i v e nb yI R ,s i n c et h e r ew a sn od i f f e r e n c ei nt h es e r u m
IgG1 titers from mice given X:31 alone (Fig. 1D, open
diamonds), or PCEP+X:31 (Fig. 1D, solid diamonds).
IgG1 titers from either group initially showed increased
titers at 2 weeks but did not show significant increase of
titers following a second IR immunization (Fig. 1D).
This observation suggests that PCEP has no adjuvant
activity when given by IR route.
Comparing the four routes, it was clear that IN (Fig.
1A) and SC (Fig. 1B) delivery provided the highest titers
of X:31-specific IgG1 titers (p < 0.05), particularly when
PCEP was included in the formulations. Evidence that
PCEP has an adjuvant effect was observed from IN, SC,
and oral immunizations, particularly since enhanced
IgG1 titers were seen as early as 2 weeks post immuni-
zation as seen for the three delivery routes (p < 0.05).
PCEP did not show an adjuvant effect as serum IgG1
titers from mice given X:31 alone or PCEP+X:31 by IR
were not significantly different.
The patterns of IgG1 responses seen were similarly
observed when assaying for serum IgG2a X:31-specific
titers (Fig. 1E-H). A primary IN immunization of X:31
alone in mice did not induce IgG2a titers until 4 weeks
post immunization where a 10-fold increase was
detected; a secondary IN immunization did not signifi-
cantly enhance serum IgG2a titers (Fig. 1E, open
squares). In contrast, mice given PCEP+X:31 showed a
100-fold increase of IgG2a titers at 2 weeks, followed by
another 10-fold increase at 4 weeks after primary immu-
nization (Fig. 1E, solid squares, p < 0.05). A secondary
immunization at 4 weeks also did not significantly
enhance IgG2a titers, although slight increases were
observed at 6 and 8 weeks (Fig. 1E, solid squares).
Administration of X:31 alone by SC induced signifi-
cant IgG2a titers at 2 and 4 weeks (Fig. 1F, open circles,
p < 0.05). Similar to IN immunization of X:31, a second-
ary SC immunization did not significantly enhance
serum IgG2a titers (Fig. 1F, open circles). The addition
of PCEP to X:31 for SC immunization greatly enhanced
IgG2a levels by 1000-fold as early as 2 weeks (Fig. 1F,
solid circles). A secondary immunization at 4 weeks
showed significant increases in IgG2a titers; however,
the increases were not as large compared to titers
observed from 2 weeks post immunization (Fig. 1F, solid
circles, p < 0.05).
Assaying for serum IgG2a titers from mice given oral
immunizations (Fig. 1G) also showed significant
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those increases were not as large as compared to levels
seen for IN and SC immunization, like the patterns
observed for assaying IgG1. IgG2a induction was gener-
ally not observed in the serum of mice regardless of the
number of X:31 immunizations except at 4 weeks where
a slight 10-fold increase was observed, but diminished
with the introduction of the second immunization (Fig.
1G, open triangles). The PCEP+X:31 formulation, how-
ever, showed a 100-fold increase of IgG2a titers at
4 weeks post immunization (Fig. 1G, solid triangles, p <
0.05). The increase in IgG2a titers persisted for the
remainder of the 8 week experiment despite a secondary
immunization (Fig. 1G, solid triangles).
As seen with IgG1 titers resulting from IR immuniza-
tion, there was little difference between IgG2a titers in
serum from mice given PCEP+X:31 or X:31 alone (Fig.
1H, solid and open diamonds, respectively), although
IgG2a titers induced from PCEP+X:31 consistently
showed slightly higher IgG2a titers during the course of
the experiment (Fig. 1H, solid diamonds). Only at
4 weeks were IgG2a levels induced from PCEP+X:31
treatment significantly higher than titers induced from
X:31 alone (Fig. 1H, double asterisk). While, the primary
immunization appeared to increase IgG2a levels from
either formulations, the secondary immunization with
PCEP+X:31 or X:31 did not significantly enhance IgG2a
titers (Fig. 1H).
Similar to the IgG1 assays, IgG2a titers were highest
following IN (Fig. 1E) and SC (Fig. 1F) delivery, particu-
larly in serum from mice that received PCEP+X:31 (p <
0.05). By the end of the 8 week experiment, serum
IgG2a titers from IN and SC delivery were consistently
at least 100-fold higher than oral or IR immunization.
While the magnitude of the IgG2a titers was not as high
in mice receiving oral immunizations, PCEP exhibited
adjuvant activity (Fig. 1G, p < 0.05), as seen with IN and
SC administration. IR immunization with PCEP+X:31
did not significantly induce higher IgG2a titers, except
at 4 weeks (Fig. 1H, double asterisk).
Interestingly, PCEP appeared to have an ability to alter
the quality of the immune response when delivered in
most of the administration routes. Table 2 shows a
comparison of IgG2a/IgG1 ratios calculated from the
Figure 1 PCEP enhances IgG1 and IgG2a X:31-specific serum titers when PCEP+X:31 is administered through intranasal, subcutaneous,
and oral routes, but not after intrarectal immunization. BALB/c mice were given PCEP+X:31 (closed symbols) or X:31 (open symbols)
through IN (A, E, squares), SC (B, F, circles), oral (C, G, triangles) and IR (D, H, diamonds) immunization. X:31-specific IgG1 (A-D) and IgG2a (E-H)
were assayed in mouse serum. Groups given PCEP+X:31 with different letters are significantly different from each other within each IgG subtype
(p < 0.05). A single asterisk indicates an adjuvant effect of PCEP during the course of the experiment, while a double asterisk indicates an
adjuvant effect only at the specified time point. Arrows indicate the time of delivery of a secondary immunization using the same delivery route
as the primary immunization.
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8 weeks post immunization as a way to evaluate whether
Th1 or Th2 immune responses were being influenced by
PCEP. Except for the IR route, IN, SC, and oral immu-
nization with PCEP+X:31 greatly altered the IgG2a/IgG1
ratios compared to administration of X:31 alone. IN and
SC immunizations nearly gave an IgG2a/IgG1 ratio of 1,
indicating a balanced Th1/Th2 response, respectively,
while the ratio following oral immunizations was
elevated from 0.66 to 0.88 (Table 2). These results
suggest that PCEP has a strong effect in enhancing
X:31-specific IgG2a titers.
Comparing mucosal immune responses from different
routes of delivery
In order to determine the delivery route(s) which
allowed for enhanced mucosal immune responses, we
assayed antigen-specific IgA and IgG antibody titers in
mucosal secretions of the lung, nasal, and vaginal cav-
ities from all mice following IN, SC, oral, and IR immu-
nizations. In lung washes, IN and SC immunizations
showed the highest X:31-specific IgA titers induced by
PCEP+X:31 (Fig 2A, solid bars, p < 0.05) and these were
significantly higher than in mice immunized with X:31
alone (Fig. 2A, open bars, p < 0.05). However, mice
given PCEP+X:31 by IN showed at least 100-fold more
antigen specific IgA titers relative to SC immunization
and a 1000-fold more IgA antibody titers compared to
oral or IR immunizations (Fig. 2A, p < 0.05). Mice that
received PCEP+X:31 by oral or IR routes showed very
little IgA production (Fig. 2A). When assaying for total
IgG in lung washes, IN, and SC immunizations of PCEP
+X:31 induced the most total IgG titers compared to
oral and IR delivery (Fig. 2B). Little response was
observed from mice immunized orally or by IR relative
to IN or SC (Fig. 2B). Although IN immunization did
induce significant IgG production (p < 0.05), SC injec-
tion showed significantly more IgG antibody production
in lung washes compared to mice immunized IN (p <
0.05). Significant adjuvant effect of PCEP in inducing
IgG titers in lungs was observed for IN, SC, and oral
immunization (Fig. 2B, p < 0.05).
The patterns observed from the mucosal immune
responses in lung washes were similar to the responses
assayed in nasal and vaginal mucosal secretions. Even
though the magnitude of absolute titers were approxi-
mately 100-fold lower in nasal washes (Fig. 3) relative to
lung washes (Fig. 2), IN immunization of PCEP+X:31
induced approximately ten fold more antigen-specific
IgA titers compared to any other administration route
(Fig. 3A, p < 0.05). Significantly higher nasal IgA titers
were observed in mice that were given PCEP+X:31 by
IN, SC, and oral immunizations compared to mice given
X:31 alone (Fig. 3A, p < 0.05), while PCEP did not seem
to have an effect on IgA titers in mice given formula-
tions by IR. As in the lung washes, SC immunization of
PCEP+X:31 showed greater antigen-specific total IgG
antibody titers compared to IN immunization (Fig. 3B,
p < 0.05). However, PCEP still had significant adjuvant
activity following IN and SC immunizations (Fig. 3B,
p < 0.05). Adjuvant activity was not observed in mice
given formulations by oral or IR routes (Fig. 3B).
Analysis of vaginal secretions showed that IN immuni-
zations of PCEP+X:31 led to significantly higher IgA
titers compared to SC, oral or IR administration (Fig.
4A, solid bars, p < 0.05). Levels of IgA production
induced by IN immunization of PCEP+X:31 were
approximately 10 times more abundant than any other
route of immunization (Fig. 4A). Similar to the IgA
titers found in lung washes, only in IN and SC immuni-
zations was the adjuvant activity of PCEP demonstrated
(p < 0.05). Interestingly, while lung and nasal washes
showed that SC immunization of PCEP+X:31 consis-
tently induced higher total IgG antibody titers than IN
(Fig. 2B, 3B), there were no significant differences
between the total IgG from mice immunized by IN or
SC (Fig. 4B). IgG titers induced by IN or SC delivery far
surpassed levels detected in vaginal secretions found in
mice immunized by oral and IR routes (Fig. 4B, p <
0.05). However, like IN and SC, oral immunization with
PCEP+X:31 showed significantly higher IgG titers com-
pared to antigen alone (p < 0.05).
IFN-g and IL-4 cytokine responses
Mouse splenocytes were isolated and stimulated
in vitro with X:31 antigen. Antigen-specific IFN-g and
IL-4 were assayed in culture supernatants in order to
determine the ability of PCEP in enhancing cytokine
production in T-helper (Th) cells in mice immunized
by various routes. SC immunization with PCEP+X:31
demonstrated the highest frequency (or number) of
IFN-g and IL-4 cytokine secreting cells per 1 × 10
6
splenocytes (Fig. 5A, B, sol i db a r s ,p<0 . 0 5 )a m o n gt h e
four routes of administration studied. An increase of
the frequency of IFN-g secreting cells was observed
when PCEP+X:31 was delivered by IN, SC and IR.
Table 2 Comparison of ratios of IgG2a to IgG1 in mice
given either PCEP+X:31 or X:31 alone
Formulation X:31 PCEP+X:31
Delivery
route
IgG2a IgG1 IgG2a/IgG1
ratio
IgG2a IgG1 IgG2a/IgG1
ratio
Intranasal 3.73 4.19 0.89 5.95 6.04 0.99
Subcutaneous 4.39 5.62 0.78 6.41 6.51 0.98
Oral 2.29 3.47 0.66 3.95 4.48 0.88
Intrarectal 3.65 4.35 0.84 3.74 4.67 0.80
Mean serum titers at 8 weeks post-primary immunization were used for the
calculations
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numbers of IFN-g secreting cells from mice given
PCEP+X:31 (solid bars) compared to X:31 (white bars)
alone (Fig. 5A, p < 0.05). IN immunization was also
the route to induce significant IL-4 production (Fig.
5B, p < 0.05). Even though observations showed that
oral administration of PCEP+X:31 led to significant
increases in serum IgG1 and IgG2a antigen-specific
titers (Fig. 1C and Fig. 1G), IgG in lung and vaginal
washes (Fig. 2B, 4B), and IgA in nasal washes
(Fig. 3A), it was interesting to note that very little
IFN-g or IL-4 producing cells were detected in spleno-
cytes (Fig. 5A, B). Moreover, X:31 alone was able to
induce high IL-4 production when delivered by SC,
with nearly the same frequency as PCEP+X:31 deliv-
ered by the same route (Fig. 5B).
Figure 2 PCEP enhances IgA and IgG antigen-specific titers in lung washes of mice following intranasal and subcutaneous
immunization. At the end of the 8 week experiment, lung washes from all the mice were collected and analyzed for X:31-specific IgA (A) and
total IgG (B) titers by ELISA after receiving either PCEP+X:31 (closed bars) or X:31 alone (open bars) following IN, SC, oral, or IR immunization.
Different letters indicate significant differences between groups that received PCEP+X:31, while asterisks indicate significant differences (i.e.
adjuvant effect) between PCEP+X:31 compared to X:31 antigen alone (p < 0.05).
Figure 3 Intranasal and subcutaneous immunization of PCEP + X:31 is effective in enhancing IgA and IgG titers in nasal secretions.
Nasal secretions were collected from mice receiving either PCEP+X:31 (closed bars) or X:31 (open bars) following IN, SC, oral, or IR immunization.
Antigen-specific IgA (A) and IgG (B) was assayed from the nasal washes. Different letters indicate significant differences between groups that
received PCEP+X:31, while asterisks indicate significant differences between PCEP+X:31 compared to X:31 antigen alone (p < 0.05).
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Most protein antigens are poorly immunologic when
given mucosally and may induce immunological toler-
ance. Therefore, mucosal immunization with proteins
requires the use of adjuvants to prevent this potential
outcome. Many studies of polyphosphazenes have clearly
showed that it can be a potent adjuvant to enhance the
magnitude and alter the quality of immune responses
[5,12-14,18,19]. However, many of these studies primarily
examined the IN and SC routes. While previous studies
showed that intramuscular (IM) and intradermal injec-
tion of PCPP and HBsAg was effective in enhancing total
IgG titers in pigs [20,21], there have been no studies that
have compared the adjuvant activity of polyphosphazenes
when delivered by various mucosal sites. Since different
mucosal surfaces have different microenvironments,
mucosal adjuvants may well have different effects at dif-
ferent mucosal sites. For this reason, we evaluated the
adjuvant activity of PCEP following vaccination via differ-
ent mucosal routes (IN, oral, IR) in comparison to par-
enteral (SC) immunization.
This is the first investigation to study the effects of
PCEP when co-delivered with influenza antigens follow-
ing different immunization routes. The results suggest
Figure 4 Enhanced IgA and IgG titers from immunized mice are also found in vaginal secretions. Vaginal mucosal washes were also
collected at the end of the 8 week experiment where X:31-specific IgA (A) and IgG (B) was assayed from mice that were immunized by IN, SC,
oral, or IR immunization with either PCEP+X:31 (closed bars) or X:31 alone (open bars). Different letters indicate significant differences between
groups that received PCEP+X:31, while asterisks indicate significant differences between PCEP+X:31 compared to X:31 antigen alone (p < 0.05).
Figure 5 PCEP significantly enhances IFN-g and IL-4 cytokine production in mice immunized via intranasal route. The spleens from mice
immunized with PCEP+X:31 (closed bars) or X:31 alone (open bars) were collected and splenocytes were subsequently isolated. The splenocytes
were stimulated with X:31 antigen and antigen-specific IFN-g (A) and IL-4 (B) were assayed to determine Th1/Th2 responses. Differences in
cytokine production as a result of IN, SC, oral, or IR immunization were also examined. Different letters indicate significant differences between
groups that received PCEP+X:31, while asterisks indicate significant differences between PCEP+X:31 compared to X:31 antigen alone (p < 0.05).
Eng et al. Journal of Immune Based Therapies and Vaccines 2010, 8:4
http://www.jibtherapies.com/content/8/1/4
Page 8 of 11that PCEP is a versatile adjuvant as indicated by its
adjuvant activity in all immunization routes tested (IN,
SC, oral and IR). We also show that PCEP effectively
enhances secretory IgA production, not only at the site
of delivery, but also, through the common mucosal
immune system, the effects can be observed at different
and distal mucosal sites. Among the routes of adminis-
tration studied here, IN delivery was clearly shown to be
the most effective in enhancing influenza X:31-specific
IgA production compared to other mucosal secretions
from the nose, lungs, and vagina. Thus, IN immuniza-
tion using PCEP as an adjuvant, may afford better pro-
tection against influenza virus infections compared to
the other routes evaluated in the present studies.
Enhancing mucosal immune responses is a key indica-
tor in determining whether polyphosphazenes have
adjuvant activity at mucosal surfaces. Clearly, IN deliv-
ery of PCEP+X:31 was able to induce significantly
higher antigen-specific IgA titers in all mucosal secre-
tions tested compared to all other routes of delivery.
The presence of secretory IgA in the mucosal secretions,
particularly from IN immunizations, is a good predictor
of protection against influenza infections, particularly
since mucosal IgA in the upper respiratory tract have
been found to be effective for the neutralization and
clearance of influenza [22]. Previous studies have shown
that PCEP enhances influenza virus neutralizing antibo-
dies [13]. IN vaccination in mice has often shown to be
the best route for protection against influenza challenge.
Various live [23], inactivated [24-30], and subunit
[31,32] influenza vaccine candidates have all shown that
IgA, induced by IN delivery, is the primary contributor
for protection against influenza, while strategies invol-
ving systemic or SC immunization either failed to
induce IgA production [26] or afforded little protection
[24,25]. In humans, secretoryI g Ar e s p o n s e sh a v ea l s o
shown to be elevated in the young and elderly given
influenza vaccines by IN [33,34], although it is currently
unknown if this relates to improved protection against
influenza. It should be noted that IgG production is also
important; while secretory IgA prevented viral-induced
pathology in the upper respiratory tract, IgG was shown
to be effective at neutralizing newly replicated virus
after infection [23]. Thus, PCEP enhances both IgA and
IgG, both of which play a major role in protection
against influenza virus infection. Nonetheless, immu-
nized mice still need to be challenged with live influenza
virus to determine if actual protection is conferred.
Our results showed that while PCEP combined with
influenza X:31 was not as potent following IR immuni-
zation, there was some evidence of adjuvant activity. IR
vaccination is an effective strategy since lymphoid tis-
sues in the rectum is a source of IgA precursors that
are found in the genital tract [35]. In addition,
immunization with hepatitis A [36] and Mycobacterium
sp. [37] following IR delivery in mice afforded enhanced
immune responses and protection. Since different anti-
gens can have different effects on magnitude and quality
of immune responses, it is likely that PCEP+X:31 may
not have been an ideal vaccine formulation for IR
immunization. Alternatively, high antigen doses may be
required for IR immunization. However, since the versa-
tility of polyphosphazenes showed adjuvant activity with
a plethora of other antigens, it is possible that polypho-
sphazenes may have adjuvant activity with antigens such
as hepatitis A or Mycobacterium.
Not surprisingly, immunization via IN was better than
oral as the former may require less antigen and adjuvant
t h a nt h el a t t e r .W h i l et h ei n t e s t i n eh a st h eg r e a t e s t
amount of lymphoid tissues, oral immunization presents
significant challenges as the gastrointestinal tract is a
very harsh environment for many antigens due to low
pH in the stomach, digestive enzymes in intestines, and
peristaltic movements. However, in this study, oral
immunization of PCEP+X:31 induced significant anti-
body responses in sera and mucosal secretions, indicat-
ing that PCEP had potent adjuvant activity when
administered orally. Previous studies showed that influ-
enza antigens formulated in immunostimulating com-
plexes (ISCOMs), did not increase serum antibody
production after oral administration compared to immu-
nization of antigen alone [38]. Also, this study is one of
a few that uses the same amount of antigen and adju-
vant for each delivery route tested. Many studies have
often compared IN and oral immunizations using much
more antigen for oral administration, where the amount
of antigen used for oral delivery can range from 2.5 to
30-fold compared to IN delivery [39-42]. While we
expected that immune responses following oral immuni-
zation would be lower in magnitude compared to IN,
being able to demonstrate PCEP adjuvant activity in
serum and mucosal secretions using a low dose antigen
for this route of immunization is a remarkable
achievement.
Not only did we show that PCEP has adjuvant activity,
but also, the polyphosphazene seems to promote a more
balanced Th1/Th2 responses based from antibody titers
in serum (Table 2), as seen previously [15]. However, a
correlation between antibody titers and cytokines
responses in the current studies was not possible. A
major factor was most likely the genetic background of
BALB/c mice which seems to demonstrate a background
expression of IL-4 not only in this study but also in pre-
vious ones as well [13,15], in contrast to other strains
such as C57 BL6 [18].
While the concept of a mucosal vaccine affording
more effective protection against pathogens that invade
mucosal sites is ideal, previous studies clearly show two
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Page 9 of 11areas of concern when delivering antigens mucosally: 1)
the ability of the antigen to retain itself and be taken up
at mucosal surfaces is often ineffective [43] and as such,
2) leads to the difficulty in eliciting immune responses
[44]. Although the mechanisms which mediate the adju-
vant activity of polyphosphazenes are not known, the
results from our studies would support the idea that the
depot effect does not contribute to mucosal adjuvant
activity of PCEP. Most mucosal adjuvants promote
mucosal immunity by 1) acting through pattern recogni-
zation, like TLR, to stimulate epithelial cells, 2) enhan-
cing antigen uptake through delivery and targeting, and
3) increase activation of APCs by upregulating costimu-
latory and MHC class II molecular expression, leading
to increased interaction and thus, stimulation of effector
B and T cells. As such, mucosal immunization remains
very practical; highly trained personnel are not required,
easier and less expensive to deliver, and no risk of nee-
dle injuries or syringe cross-contamination. Further ben-
efits from such attributes also lead to improved
compliance, which can be particularly important in
developing regions of the world. As a result, the benefits
of developing effective mucosal vaccines overcome the
present barrier of challenges. Evolving strategies to
improve antigen immunogenicity, delivery, and long-
lasting effects for mucosal vaccines are constantly being
developed.
Even though most studies of polyphosphazenes have
been in mice, its adjuvant activity has been shown in
rhesus monkeys [10], sheep [14], and pigs [20], without
notable side effects. In addition, PCPP has been safely
tested in Phase I clinical trials as an adjuvant with an
influenza vaccine on young and elderly human adults
with enhanced immune responses in sera and no side
effects [45]. PCPP also been used in clinical trials on a
HIV vaccine [46]. Clinical studies of PCEP have yet to
be reported. Regardless, the use of polyphosphazenes in
larger animals seems very promising as an effective and
safe adjuvant, emphasizing its potential as an attractive
adjuvant candidate for vaccine development.
Conclusions
The polyphosphazene PCEP is a powerful mucosal adju-
vant that can significantly enhance systemic and muco-
sal immune responses following immunization in a
variety of routes. This study showed that polyphospha-
zenes delivered intranasally may be the ideal route of
administration to enhance mucosal immunity or protec-
tion against influenza. We observed the potential of
PCEP to enhance IgG2a and IgA levels, an observation
seen previously with other adjuvants [47]. This suggests
that the combined enhancement of cell mediated
(IgG2a) and humoral (IgA) responses may be ideal for a
cooperative effect in providing clearance and protection
not only against influenza infections, but also possibly
other respiratory pathogens, indicating its potential as
an adjuvant for mucosal vaccines.
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